Get started
Author

Derlis Gonzalez

Observed names: D E Gonzalez, Derlis E. Gonzalez, Derlis E. González, Derlis Emilio Gonzalez-Rodriguez, Derlis Gonzalez Rodríguez
OpenAlex ID: A5103798123
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial
2019 · Raphael Schiffmann, Ozlem Goker‐Alpan, et al. · Journal of Inherited Metabolic Disease · 148
PDF
Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study
2012 · Derlis E. Gonzalez, Hadhami Ben Turkia, et al. · American Journal of Hematology · 87
PDF
Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease
2012 · Hadhami Ben Turkia, Derlis E. Gonzalez, et al. · American Journal of Hematology · 72
PDF
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long‐term data from phase III clinical trials
2015 · Derralynn A. Hughes, Derlis E. Gonzalez, et al. · American Journal of Hematology · 52
PDF
Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase
2016 · Ari Zimran, Derlis Emilio Gonzalez-Rodriguez, et al. · Blood Cells Molecules and Diseases · 44
PDF
Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach
2018 · Myrna Candelaria, Derlis Gonzalez, et al. · Cancer Chemotherapy and Pharmacology · 42
PDF
Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease
2014 · Ari Zimran, Derlis Emilio Gonzalez-Rodriguez, et al. · Blood Cells Molecules and Diseases · 35
PDF
Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study
2019 · Myrna Candelaria, Derlis E. González, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 33
Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4 years in phase 3 trials
2016 · Ari Zimran, Deborah Elstein, et al. · Blood Cells Molecules and Diseases · 30
PDF
Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease
2023 · Derralynn Hughes, Derlis Gonzalez, et al. · Genetics in Medicine · 29
PDF
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
2015 · Lubor Goláň, Ozlem Goker-Alpan, et al. · Drug Design Development and Therapy · 22
PDF
Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease
2016 · Gregory M. Pastores, Hadhami Ben Turkia, et al. · Blood Cells Molecules and Diseases · 15
PDF
1261 Enzyme Replacement Therapy with Velaglucerase Alfa Improves Key Clinical Parameters in a Pediatric Subgroup with Type 1 Gaucher Disease
2010 · A Zimran, D E Gonzalez, et al. · Pediatric Research · 4
A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Patients with Gaucher Disease.
2012 · Ari Zimran, Derlis Emilio Gonzalez-Rodriguez, et al. · Blood · 3
157. Enzyme replacement therapy with velaglucerase alfa significantly improves key clinical parameters in type 1 Gaucher disease: Positive results from a randomized, double-blind, global, phase III study
2010 · Ari Zimran, Derlis Gonzalez, et al. · Molecular Genetics and Metabolism · 3
PRX-102 for treating Fabry disease: immunogenicity and PK results from a phase 1-2 study
2017 · David Warnock, Derralynn Hughes, et al. · Molecular Genetics and Metabolism · 2
Novel treatment for Fabry disease: IV administration of plant derived alpha-gal-A enzyme safety and efficacy interim report
2016 · Derralynn Hughes, Simeon Boyd, et al. · Molecular Genetics and Metabolism · 2
156. Enzyme replacement therapy with velaglucerase alfa improves key clinical parameters in a pediatric subgroup with type 1 Gaucher disease
2010 · Ari Zimran, Derlis Gonzalez, et al. · Molecular Genetics and Metabolism · 2
eP148: Long-term safety and efficacy of pegunigalsidase alfa: A multicenter extension study in adult patients with Fabry disease
2022 · Derlis Gonzalez, Gustavo Maegawa, et al. · Genetics in Medicine · 1
PDF
One-year follow up of Fabry disease patients treated by IV administration of a plant derived alpha-Gal-A enzyme: safety and efficacy
2017 · Derralynn Hughes, Simeon Boyd, et al. · Molecular Genetics and Metabolism · 1
Therapeutic goals and normal clinical values achieved within 4years of initiating velaglucerase alfa in treatment-naïve patients with Gaucher disease in phase 3 studies
2016 · Deborah Elstein, Ari Zimran, et al. · Molecular Genetics and Metabolism · 1
Hematopoietic Stem Cell Transplant Activity in Latin America: Predominant Increase in Autologous and Modest Increase in Allogeneic HCT with High Use of Unrelated Cord Blood Grafts
2015 · Juliana Martinez Rolon, Helen Baldomero, et al. · Blood · 1
Long-term safety and efficacy of taliglucerase alfa in pediatric patients with Gaucher disease who were treatment-naïve previously treated with immiglucerase
2015 · Ari Zimran, Derlis Emilio Gonzalez-Rodriguez, et al. · Molecular Genetics and Metabolism · 1
Comparison of taliglucerase alfa 30U/kg and 60U/kg in treatment-naïve pediatric patients with Gaucher disease
2015 · Ari Zimran, Derlis Emilio Gonzalez-Rodriguez, et al. · Molecular Genetics and Metabolism · 1
A multicenter, double-blind, randomized safety and efficacy study of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease
2013 · Ari Zimran, Derlis Emilio Gonzalez-Rodriguez, et al. · Molecular Genetics and Metabolism · 1
Works count: 31
Citation count: 632
H-index: 12
I10-index: 12
Year
Topic
Type